Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer.
作者： Wujian Zheng , Qi Feng , Jiao Liu , Yanke Guo , Lvfen Gao
关键词:
摘要: Cisplatin (DDP) is currently one of the most commonly used chemotherapeutic drugs for treating ovarian and lung cancer. However, resistance to cisplatin common it often leads therapy failure. In addition, precise mechanism still in its infancy. this study, we demonstrated that oxidative pentose phosphate pathway (PPP) enzyme 6-phosphogluconate dehydrogenase (6PGD) promotes resistance. We showed cisplatin-resistant cancer cells (C13* A549DDP), had higher levels 6PGD compared their cisplatin-sensitive counterparts (OV2008 A549). Furthermore, patients with have worse survival outcomes relative lower expression. Interestingly, found upregulation was due decreased expression miR-206 miR-613, which target enzyme. further demonstrate suppressing using shRNA, inhibitor or miR-206/miR-613, either as single agents combination, could sensitize treatment thereby improving therapeutic efficacy cisplatin. Taken together, our results suggest serves a novel potential overcome
frontiersin.org
core.ac.uk
doaj.org参考文章(28)
S Seah, ICC Low, JL Hirpara, K Sachaphibulkij, G Kroemer, C Brenner, Shazib Pervaiz, None, Activation of surrogate death receptor signaling triggers peroxynitrite-dependent execution of cisplatin-resistant cancer cells Cell Death and Disease. ,vol. 6, ,(2015) , 10.1038/CDDIS.2015.299
S Zhang, C Shan, G Kong, Y Du, L Ye, X Zhang, MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK) Oncogene. ,vol. 31, pp. 3607- 3620 ,(2012) , 10.1038/ONC.2011.523
Hailan Liu, Yang Liu, Jian-Ting Zhang, A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction Molecular Cancer Therapeutics. ,vol. 7, pp. 263- 270 ,(2008) , 10.1158/1535-7163.MCT-07-0445
N. Pabla, Z. Dong, Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies Kidney International. ,vol. 73, pp. 994- 1007 ,(2008) , 10.1038/SJ.KI.5002786
Shaloam Dasari, Paul Bernard Tchounwou, Cisplatin in cancer therapy: Molecular mechanisms of action European Journal of Pharmacology. ,vol. 740, pp. 364- 378 ,(2014) , 10.1016/J.EJPHAR.2014.07.025
Jun Fan, Changliang Shan, Hee-Bum Kang, Shannon Elf, Jianxin Xie, Meghan Tucker, Ting-Lei Gu, Mike Aguiar, Scott Lonning, Huaibin Chen, Moosa Mohammadi, Laura-Mae P. Britton, Benjamin A. Garcia, Maša Alečković, Yibin Kang, Stefan Kaluz, Narra Devi, Erwin G. Van Meir, Taro Hitosugi, Jae Ho Seo, Sagar Lonial, Manila Gaddh, Martha Arellano, Hanna J. Khoury, Fadlo R. Khuri, Titus J. Boggon, Sumin Kang, Jing Chen, Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex Molecular Cell. ,vol. 53, pp. 534- 548 ,(2014) , 10.1016/J.MOLCEL.2013.12.026
Rob A. Cairns, Isaac S. Harris, Tak W. Mak, Regulation of cancer cell metabolism Nature Reviews Cancer. ,vol. 11, pp. 85- 95 ,(2011) , 10.1038/NRC2981
Y Zhao, E B Butler, M Tan, Targeting cellular metabolism to improve cancer therapeutics Cell Death and Disease. ,vol. 4, pp. 0- ,(2013) , 10.1038/CDDIS.2013.60
Jian-Bin Wang, Jon W. Erickson, Reina Fuji, Sekar Ramachandran, Ping Gao, Ramani Dinavahi, Kristin F. Wilson, Andre L.B. Ambrosio, Sandra M.G. Dias, Chi V. Dang, Richard A. Cerione, Targeting mitochondrial glutaminase activity inhibits oncogenic transformation Cancer Cell. ,vol. 18, pp. 207- 219 ,(2010) , 10.1016/J.CCR.2010.08.009
Ethan Yixun Xu, Ally Perlina, Heather Vu, Sean P. Troth, Richard J. Brennan, Amy G. Aslamkhan, Qiuwei Xu, Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants. Chemical Research in Toxicology. ,vol. 21, pp. 1548- 1561 ,(2008) , 10.1021/TX800061W